Ingmar Bruns Acquires 20,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Ingmar Bruns purchased 20,000 shares of the company’s stock in a transaction dated Thursday, February 6th. The stock was purchased at an average price of $2.28 per share, with a total value of $45,600.00. Following the completion of the purchase, the insider now directly owns 36,629 shares in the company, valued at $83,514.12. The trade was a 120.27 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Zentalis Pharmaceuticals Stock Up 12.5 %

Shares of NASDAQ:ZNTL opened at $2.43 on Friday. Zentalis Pharmaceuticals, Inc. has a 12-month low of $1.61 and a 12-month high of $18.07. The business has a fifty day simple moving average of $2.67 and a 200 day simple moving average of $3.14.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. On average, analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Institutional Trading of Zentalis Pharmaceuticals

Large investors have recently bought and sold shares of the business. Erste Asset Management GmbH acquired a new stake in Zentalis Pharmaceuticals during the 3rd quarter worth about $37,000. Paloma Partners Management Co acquired a new stake in Zentalis Pharmaceuticals during the 3rd quarter worth about $37,000. Prudential Financial Inc. acquired a new stake in Zentalis Pharmaceuticals during the 4th quarter worth about $39,000. Cerity Partners LLC acquired a new stake in Zentalis Pharmaceuticals during the 4th quarter worth about $40,000. Finally, Aigen Investment Management LP acquired a new stake in Zentalis Pharmaceuticals during the 3rd quarter worth about $41,000.

Analyst Ratings Changes

A number of brokerages have recently commented on ZNTL. UBS Group dropped their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. HC Wainwright dropped their price target on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Wells Fargo & Company dropped their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Guggenheim dropped their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Finally, Wedbush reaffirmed a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Zentalis Pharmaceuticals has a consensus rating of “Hold” and an average target price of $8.24.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.